

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT06500702

Status	RECRUITING
Phase	Phase 2
Sponsor	Sanofi
Enrollment	84 participants

Key Eligibility Criteria

Inclusion (8)

- Biopsy report indicative of primary FSGS or primary MCD, with supportive clinical presentation per Investigator's judgement.
 - UPCR ≤ 3 g/g at screening, or ≤ 1.5 g/g in those with eGFR ≥ 60 .
 - eGFR ≥ 45 mL/min/1.73 m² at screening.
 - Documented history of UPCR (or 24-hour urine protein) reduction by $\geq 40\%$ in response to corticosteroid or other immunosuppressive therapy when pre-treatment UPCR was ≥ 3.5 g/g (or pre-treatment 24-hr urine protein was ≥ 3.5 g/day if 24-hour urine protein is used).
 - ≥ 10 mg/day prednisone or equivalent and stable starting at least 1 week prior to randomization.
- ... and 3 more (see full listing online)

Exclusion (4)

- Genetic or secondary FSGS or MCD. Those with APOL1 risk alleles are eligible.
- Collapsing variant of FSGS.
- ESKD requiring dialysis or transplantation.
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (70 total)

Investigational Site Number : 8400007, Birmingham, Alabama, United States
Investigational Site Number : 8400015, Orange, California, United States
Investigational Site Number : 8400012, San Francisco, California, United States
... and 67 more locations

<https://clinicaltrials.gov/study/NCT06500702>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.